|

Abraxane Clinical Trials

6 actively recruiting trials across 2 locations

No change since May 2026

Also known as: Abraxane Injectable Product

Pipeline

Phase 1: 2Phase 2: 3Phase 1/2: 1

Top Sponsors

  • Zhejiang Cancer Hospital1
  • The First Affiliated Hospital with Nanjing Medical University1
  • Phanes Therapeutics1
  • H. Lee Moffitt Cancer Center and Research Institute1
  • Chinese PLA General Hospital1

Indications

Other4 trials

Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Patients
Phase 1
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
Phase 1
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
Phase 2
Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard Therapy
Phase 2

Duarte, California1 trial

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Phase 1/2

Tampa, Florida1 trial

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

Moffitt Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.